goprolytix/General Structure of ANSN-Based Florogenic Substrates/1mg/SN-13a
goprolytix/General Structure of ANSN-Based Florogenic Substrates/1mg/SN-17a
goprolytix/General Structure of ANSN-Based Florogenic Substrates/1mg/SN-17c
goprolytix/General Structure of ANSN-Based Florogenic Substrates/1mg/SN-18
goprolytix/General Structure of ANSN-Based Florogenic Substrates/1mg/SN-20
goprolytix/General Structure of ANSN-Based Florogenic Substrates/1mg/SN-45
goprolytix/General Structure of ANSN-Based Florogenic Substrates/1mg/SN-54
goprolytix/General Structure of ANSN-Based Florogenic Substrates/1mg/SN-59
goprolytix/General Structure of ANSN-Based Florogenic Substrates/1 mg/SN-X
goprolytix/a2–plasmin inhibitor and fibrinolysis/1 mg, 100 µg/HA2AP-0230
rPeptide/Anti-Human Beta-Amyloid 6D11, Monoclonal/1.0mg/TA-3021-2
goprolytix/Domain Structure of Tafi/1 mg, 50 µg/TAFI-01
goprolytix/Human “Angiostatin.”/1 mg, 500µg/ANG-01
rPeptide/Anti-Human Beta-Amyloid 6D11, Monoclonal/100ug/TA-3021-1
